1 Some #irads voice concerns that the “other” IO (immuno-oncology) will “put an end to our” IO (interventional oncology). Sounds similar to the meaningless chatter around 2008 when Sorafenib first came out. Complete nonsense then and now. Few thoughts:

2 STOP worrying and instead use power of IO^2 and think bigger than your niche. We will only win together if we think together. Work with your friends from med onc, hepatology and immunology / immunobiology! This is not a zero sum game. Never was.

3 STOP indoctrinating junior people that research is less important than brilliant clinical hands on skills. Encountering plenty of folks who don’t take Dotter’s advice serious and want to raise another generation of easily replaceable “high-priced plumbers”. Won’t survive!

4 START sending trainees / junior faculty to tumor boards and oncology conferences, make sure there is protected time to dedicate to research and become an HCC EXPERT. Some folks graduate having done 100 ablations but don’t know what the BCLC is. Unacceptable!!!

5 Absurd to still encounter otherwise extremely experienced senior IRs who don’t “believe” in our own technological advances like “CBCT”. If you want to practice IR 1990 style, you will be extinct by evolution. No “living legend” bonus applies! Evidence does apply. Always!